Cancer Epigenetics Program and Kidney Keystone Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Epigenetics. 2013 May;8(5):486-93. doi: 10.4161/epi.24552. Epub 2013 May 1.
Recent sequencing studies of clear cell (conventional) renal cell carcinoma (ccRCC) have identified inactivating point mutations in the chromatin-modifying genes PBRM1, KDM6A/UTX, KDM5C/JARID1C, SETD2, MLL2 and BAP1. To investigate whether aberrant hypermethylation is a mechanism of inactivation of these tumor suppressor genes in ccRCC, we sequenced the promoter region within a bona fide CpG island of PBRM1, KDM6A, SETD2 and BAP1 in bisulfite-modified DNA of a representative series of 50 primary ccRCC, 4 normal renal parenchyma specimens and 5 RCC cell lines. We also interrogated the promoter methylation status of KDM5C and ARID1A in the Cancer Genome Atlas (TCGA) ccRCC Infinium data set. PBRM1, KDM6A, SETD2 and BAP1 were unmethylated in all tumor and normal specimens. KDM5C and ARID1A were unmethylated in the TCGA 219 ccRCC and 119 adjacent normal specimens. Aberrant promoter hypermethylation of PBRM1, BAP1 and the other chromatin-modifying genes examined here is therefore absent or rare in ccRCC.
最近对透明细胞(常规)肾细胞癌(ccRCC)的测序研究鉴定了染色质修饰基因 PBRM1、KDM6A/UTX、KDM5C/JARID1C、SETD2、MLL2 和 BAP1 的失活点突变。为了研究这些肿瘤抑制基因在 ccRCC 中失活是否是异常超甲基化的机制,我们在代表性的 50 例原发性 ccRCC、4 例正常肾实质标本和 5 例 RCC 细胞系的经亚硫酸氢盐修饰的 DNA 中对 PBRM1、KDM6A、SETD2 和 BAP1 的启动子区域进行了测序。我们还在癌症基因组图谱(TCGA)ccRCC Infinium 数据集中检测了 KDM5C 和 ARID1A 的启动子甲基化状态。所有肿瘤和正常标本中 PBRM1、KDM6A、SETD2 和 BAP1 均未甲基化。TCGA 219 例 ccRCC 和 119 例相邻正常标本中 KDM5C 和 ARID1A 均未甲基化。因此,ccRCC 中不存在或罕见 PBRM1、BAP1 和其他所检查的染色质修饰基因的异常启动子超甲基化。